[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 690
Citations 0
News From the Food and Drug Administration
December 15, 2015

Antibody Approved for Asthma

JAMA. 2015;314(23):2497. doi:10.1001/jama.2015.16802

Mepolizumab, marketed as Nucala, has been approved for use with other asthma medications as maintenance therapy for patients with asthma who have a history of exacerbations despite taking their current asthma treatment.

The drug is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells. Mepolizumab, which is given by injection every 4 weeks, reduces severe asthma attacks by reducing blood levels of eosinophils (http://1.usa.gov/20wB823).

First Page Preview View Large
First page PDF preview
First page PDF preview